U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H12N4O3S
Molecular Weight 280.303
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFAMETER

SMILES

COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1

InChI

InChIKey=GPTONYMQFTZPKC-UHFFFAOYSA-N
InChI=1S/C11H12N4O3S/c1-18-9-6-13-11(14-7-9)15-19(16,17)10-4-2-8(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)

HIDE SMILES / InChI

Molecular Formula C11H12N4O3S
Molecular Weight 280.303
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.sigmaaldrich.com/catalog/product/sigma/s0383?lang=es®ion=ES http://www.medchemexpress.com/sulfameter.html

Sulfametoxydiazine (INN) or sulfamethoxydiazine (USAN: sulfameter) is a long-acting sulfonamide antibacterial, shows bacteriostatic effects against Gram positive and Gram negative bacteria in vivo. It is used as a leprostatic agent and in the treatment of urinary tract infections. Orally active. Sulfonamides block the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase. Sulfonamides are competitive inhibitors of bacterial para-aminobenzoic acid (PABA), which is required for bacterial synthesis of folic acid. Sulfameter is a dihydrofolate reductase (DHFR) inhibitor. Mode of resistance is via the alteration of dihydropteroate synthase or alternative pathway for folic acid synthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
SULLA

Approved Use

Unknown

Launch Date

1966
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
44.2 μg/mL
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAMETER plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1599 μg × h/mL
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAMETER plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
24 h
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAMETER plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
250 mg/kg 1 times / day steady, oral
Recommended
Dose: 250 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 250 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
500 mg/kg 1 times / day steady, oral
Recommended
Dose: 500 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Nasal stuffiness, Edema lip...
AEs leading to
discontinuation/dose reduction:
Nasal stuffiness (2 patients)
Edema lip (1 patient)
Leukopenia (1 patient)
Sources:
2 g single, oral
Studied dose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: unknown
Sources:
AEs

AEs

AESignificanceDosePopulation
Edema lip 1 patient
Disc. AE
500 mg/kg 1 times / day steady, oral
Recommended
Dose: 500 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Leukopenia 1 patient
Disc. AE
500 mg/kg 1 times / day steady, oral
Recommended
Dose: 500 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nasal stuffiness 2 patients
Disc. AE
500 mg/kg 1 times / day steady, oral
Recommended
Dose: 500 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg/kg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Gene expression signature-based screening identifies new broadly effective influenza a antivirals.
2010-10-04
Determination of sulfonamides in soil samples based on alumina-coated magnetite nanoparticles as adsorbents.
2010-04-30
Determination of 76 pharmaceutical drugs by liquid chromatography-tandem mass spectrometry in slaughterhouse wastewater.
2009-11-20
Fast and selective extraction of sulfonamides from honey based on magnetic molecularly imprinted polymer.
2009-11-11
Analysis of sulfonamides in environmental water samples based on magnetic mixed hemimicelles solid-phase extraction coupled with HPLC-UV detection.
2009-11
N-(4,6-Dimethyl-pyrimidin-2-yl)-4-(oxolan-2-ylamino)benzene-sulfonamide.
2009-10-28
A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection.
2009-10-23
On-line coupling of dynamic microwave-assisted extraction to solid-phase extraction for the determination of sulfonamide antibiotics in soil.
2009-08-26
[Investigation of sulfonamides and tetracyclines antibiotics in soils from various vegetable fields].
2009-06-15
Multiresidue determination of sulfonamides in chicken meat by polymer monolith microextraction and capillary zone electrophoresis with field-amplified sample stacking.
2008-09-26
ELISA for sulfonamides and its application for screening in water contamination.
2008-08-13
Desolvation kinetics of sulfameter solvates.
2008-06
[Simultaneous determination of sulfonamides and fluoroquinolones residues in chicken by high performance liquid chromatography-electrospray tandem mass spectrometry].
2008-05
Characterization of integrons-mediated antimicrobial resistance among Escherichia coli strains isolated from bovine mastitis.
2008-02-05
Analytical methods for multiresidue determination of sulfonamides and trimethoprim in meat and ground water samples by CE-MS and CE-MS/MS.
2007-11
Determination of sulphonamides in animal tissues by high performance liquid chromatography with pre-column derivatization of 9-fluorenylmethyl chloroformate.
2007-11
Development of an immunochromatographic lateral-flow test strip for rapid detection of sulfonamides in eggs and chicken muscles.
2007-03-21
Hapten synthesis and development of polyclonal antibody-based multi-sulfonamide immunoassays.
2006-06-28
Simultaneous determination of 16 sulfonamides in honey by liquid chromatography/tandem mass spectrometry.
2006-01-03
[Qualification and quantification of 10 sulfonamides in animal feedstuff by high performance liquid chromatography-electrospray tandem mass spectrometry].
2005-07
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005-06
Complementary use of model-free and modelistic methods in the analysis of solid-state kinetics.
2005-05-26
Possible association between different congenital abnormalities and use of different sulfonamides during pregnancy.
2004-06
Liquid chromatography-fluorescence detection for simultaneous analysis of sulfonamide residues in honey.
2003-06
Hydrogen bonding in sulfonamides.
2001-12
Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.
1996-04
Anticryptosporidial activity is associated with specific sulfonamides in immunosuppressed rats.
1991-04
Patents

Sample Use Guides

In Vivo Use Guide
Sources: DOI: 10.1002/cpt1969104591
Loading dose first-day only (single dose): 1500 mg (3 tablets) Daily maintenance (single dose at 24 hour intervals): 500 mg (1 tablet).
Route of Administration: Oral
Titrations of antibacterial activity were carried out by making twofold serial dilutions dilutions of plasma or serum and adding an equal volume (0.5 ml.) of a 10-5 dilution of an overnight culture of a strain of Escherichia coli which had been isolated from the peritoneal fluid of a patient with peritonitis and which was consistently sensitive to 0.30 mg. of sulfamethoxydiazine per 100 ml. of broth. Study of antibacterial titers showed that at 1: 64 the sulfonamide concentrations varied from 7 to 14 mg. per 100 ml
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:25:16 GMT 2025
Edited
by admin
on Wed Apr 02 09:25:16 GMT 2025
Record UNII
3L179F09D6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFAMETER
MI   ORANGE BOOK   USAN  
USAN  
Official Name English
SULFAMETOXYDIAZINE
INN   WHO-DD  
INN  
Preferred Name English
N(SUP 1)-(5-METHOXY-2-PYRIMIDINYL)SULFANILAMIDE
Systematic Name English
ULTRAX
Brand Name English
AHR-857
Code English
SULFAMETHOXYDIAZINE
Common Name English
SH-613
Code English
SULFAMETER [MI]
Common Name English
SULFAMETER [USAN]
Common Name English
Sulfametoxydiazine [WHO-DD]
Common Name English
BENZENESULFONAMIDE, 4-AMINO-N-(5-METHOXY-2-PYRIMIDINYL)-
Systematic Name English
SULFAMETHOXYPYRIMIDINE
Common Name English
BAY-5400
Code English
sulfametoxydiazine [INN]
Common Name English
SULFAMETER [ORANGE BOOK]
Common Name English
NSC-757874
Code English
NSC-683528
Code English
SULPHAMETHOXYDIAZINE
Common Name English
SULLA
Brand Name English
Classification Tree Code System Code
WHO-ATC J01ED04
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
NCI_THESAURUS C29739
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
Code System Code Type Description
NSC
757874
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
NCI_THESAURUS
C66568
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
DRUG CENTRAL
2511
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
CAS
651-06-9
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
ECHA (EC/EINECS)
211-480-8
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
CHEBI
53727
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
MERCK INDEX
m10316
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID5023613
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
FDA UNII
3L179F09D6
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
PUBCHEM
5326
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
MESH
D013417
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200359
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
WIKIPEDIA
SULFAMETOXYDIAZINE
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
DRUG BANK
DB06821
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
EVMPD
SUB10714MIG
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
SMS_ID
100000083252
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
NSC
683528
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
INN
1335
Created by admin on Wed Apr 02 09:25:16 GMT 2025 , Edited by admin on Wed Apr 02 09:25:16 GMT 2025
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY
A long-acting sulfonamide antibacterial. It is used as a leprostatic agent and in the treatment of urinary tract infections.